Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP9X inhibits SOX2. 2 / 2

| 2

➶

reach

"Usp9x KD blocked the induction of SOX2 by vemurafenib or MEKi treatment in melanoma cell lines with mutant BRAF, A375 (XREF_FIG), SK-Mel28 (XREF_FIG) and wild type BRAF, SK-Mel147 (XREF_FIG)."

33613844

➶

reach

"Furthermore, we found that Usp9x KD reduced the half-life of SOX2 in the presence of cycloheximide from 6 to 4 h (XREF_FIG), suggesting that in the absence of new protein translation, Usp9x can control pre-existing SOX2 levels."

33613844

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...